Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPP-3001
- Development stage
- Preclinical
- Lead developer
- Beta Pharma
- Modality
- Peptides
01
Overview
BPP-3001 is an investigational therapeutic candidate being developed by Beta Pharma for weight management and the treatment of obesity. It targets the glucagon-like peptide (GLP) system, specifically acting as an agonist of the glucagon-like peptide 1 receptor (GLP1R). By mimicking the action of endogenous GLP-1, BPP-3001 is designed to regulate appetite, increase satiety, and reduce caloric intake. It is part of Beta Pharma's metabolic disease pipeline, which utilizes a distinct naming convention (BPP) for its peptide-based programs, differentiating them from the company's small molecule (BPI) oncology portfolio.
02
Targets
Beyond the preview
Go deeper on BPP-3001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPP-3001.